Resources
BeiGene Medical Europe

Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer

 Back View
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
 POSTER   09/2020
 Download  View

For more information about this resource, please submit a medical information request.

Rating

Rate this resource

Related resources

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
Tislelizumab - Mode of Action
Tislelizumab - Mode of Action
 Back

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service